Testing a blood thinner to prevent pregnancy complications in high-risk mothers

Plain-English translation of NCT06004674 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called enoxaparin—a blood thinner given as a daily injection—can help prevent serious pregnancy problems in women who have had complications before. Researchers believe that problems with how the placenta develops blood vessels may cause some pregnancies to go wrong, and they want to see if this medication can reduce that risk and help you have a healthier pregnancy this time.

Some women experience serious pregnancy complications like early delivery, stillbirth, or high blood pressure, often because the placenta doesn't develop its blood vessels properly. Doctors hope that this medication might prevent these problems from happening again in future pregnancies.

Do you qualify?

You likely qualify if…

you have had a serious complication in a prior pregnancy, such as early delivery before 37 weeks, a baby with poor growth, severe high blood pressure during pregnancy, or stillbirth
testing of your placenta from that prior pregnancy showed evidence of blood vessel problems, confirmed by a placental pathologist
you are currently pregnant with a single baby and are less than 16 weeks and 6 days along

You likely don't qualify if…

you are already taking blood-thinning medications like warfarin or heparin
you have a known major birth defect in the current pregnancy
you have active major bleeding, very low platelet counts, or an allergy to this medication or heparin
you have severe kidney or liver disease
you have a mechanical heart valve

What participation looks like

If you join this trial, you'll be randomly assigned to either take the medication or receive standard pregnancy care. If assigned to the medication group, you'll give yourself a daily injection starting around 12 weeks of pregnancy and continuing until 36 weeks. You'll have blood drawn at a few visits during pregnancy and at delivery, and the study team will check in with you about a week after starting the medication to make sure you're doing well. The entire study follows you through the end of your pregnancy.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(1 site)

United States

NorthShore University HealthSystem, Evanston, Illinois